Thermo Fisher Scientific (NYSE: TMO ) reported earnings on Oct. 24. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Sep. 29 (Q3), Thermo Fisher Scientific beat expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded and GAAP earnings per share expanded significantly.
Gross margins grew, operating margins contracted, net margins grew.
Thermo Fisher Scientific reported revenue of $3.09 billion. The 16 analysts polled by S&P Capital IQ predicted revenue of $2.99 billion on the same basis. GAAP reported sales were 3.8% higher than the prior-year quarter's $2.97 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $1.19. The 20 earnings estimates compiled by S&P Capital IQ predicted $1.16 per share. GAAP EPS of $0.80 for Q3 were 16% higher than the prior-year quarter's $0.69 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 43.9%, 190 basis points better than the prior-year quarter. Operating margin was 11.9%, 50 basis points worse than the prior-year quarter. Net margin was 9.4%, 50 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $3.12 billion. On the bottom line, the average EPS estimate is $1.27.
Next year's average estimate for revenue is $12.28 billion. The average EPS estimate is $4.82.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 551 members out of 572 rating the stock outperform, and 21 members rating it underperform. Among 160 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 157 give Thermo Fisher Scientific a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Thermo Fisher Scientific is outperform, with an average price target of $63.97.